Get the Stockscreener App
328.97
1.44%
4.67
Pre-market:
328.97
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $328.97, with a volume of 1.90M.
It is up +1.44% in the last 24 hours and up +3.53% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$324.30
Open:
$324.09
24h Volume:
1.90M
Relative Volume:
0.73
Market Cap:
$177.14B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
25.43
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
-3.71%
1M Performance:
+3.53%
6M Performance:
+10.75%
1Y Performance:
+23.16%
1-Day Range:
$323.55
$329.20
1-Week Range:
$319.79
$341.46
52-Week Range:
$261.43
$346.38
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
328.97 | 174.63B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,073.29 | 964.11B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.55 | 514.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
221.89 | 390.15B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
146.16 | 271.72B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
111.01 | 268.70B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - sharewise.com
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses - Benzinga
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate - Yahoo Finance
Amgen Inc. $AMGN Shares Acquired by Global Wealth Management Investment Advisory Inc. - MarketBeat
Decliners Report: Why Amgen Inc stock could rally in 20252025 Breakouts & Breakdowns & Weekly Top Performers Watchlists - moha.gov.vn
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman - Benzinga
Ro partners with Amgen to study barriers to obesity care, GLP-1 access - marketscreener.com
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance - FinancialContent
Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage - marketscreener.com
Amgen (AMGN) Reveals Promising Results from MariTide Phase 2 Stu - GuruFocus
Amgen Inc. $AMGN Shares Acquired by PKO Investment Management Joint Stock Co - MarketBeat
Nordea Investment Management AB Acquires 22,465 Shares of Amgen Inc. $AMGN - MarketBeat
Trickle of Data On Amgen’s MariTide Hints At Potential Of Lower Maintenance Dosing - Citeline News & Insights
Amgen to announce data on obesity drug MariTide at healthcare conference - WNWN-FM
Amgen Inc. $AMGN Shares Bought by Citizens Financial Group Inc. RI - MarketBeat
Amgen says MariTide helped trial patients maintain weight loss - The Mighty 790 KFGO
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules - BioSpace
Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event - MarketBeat
Amgen’s MariTide Patients Maintain Weight Loss for Two Years - Bloomberg.com
Amgen's Maritide: A Breakthrough in Diabetes Management - Devdiscourse
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight - TradingView — Track All Markets
Key Executive Transition from Amgen (AMGN) to BioMarin - GuruFocus
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Lobbying Update: $37,500 of AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. $AMGN Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Meeder Asset Management Inc. Purchases 27,584 Shares of Amgen Inc. $AMGN - MarketBeat
Tema Etfs LLC Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
First Horizon Corp Takes Position in Amgen Inc. $AMGN - MarketBeat
Amgen Buys U.K. Biotech Company - Los Angeles Business Journal
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors - simplywall.st
Amgen Stock Holds Its Ground: What The Latest Price Action, Ratings and Pipeline Signals Mean For In - AD HOC NEWS
Amgen stock slides into weekend as JPMorgan healthcare conference looms - TechStock²
Nepsis Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After Its 28% One Year Share Price Gain? - Yahoo Finance
Amgen to acquire Dark Blue for cancer drug DBT 3757 - BioXconomy
State of Alaska Department of Revenue Sells 3,034 Shares of Amgen Inc. $AMGN - MarketBeat
Oregon Public Employees Retirement Fund Buys 15,172 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Nova R Wealth Inc. - MarketBeat
Amgen (NASDAQ:AMGN) Stock Rating Upgraded by UBS Group - MarketBeat
Amgen Inc. $AMGN Shares Bought by Ferguson Wellman Capital Management Inc. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) aligns with nasdaq composite life sciences - Kalkine Media
Can Amgen Inc. stock rebound after recent weaknessQuarterly Earnings Report & Technical Pattern Based Signals - ulpravda.ru
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
How Amgen Inc. stock valuations compare to rivalsWeekly Profit Report & Growth Oriented Trading Recommendations - ulpravda.ru
Amgen (AMGN) Valuation Check After DISCO Oncology Deal And Fresh Analyst Optimism - simplywall.st
Amgen (NASDAQ:AMGN) Price Target Raised to $319.00 at Truist Financial - MarketBeat
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating - MarketScreener
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan - TipRanks
Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? - Yahoo Finance
Amgen acquires British Dark Blue Therapeutics for USD 840m - medwatch.com
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):